 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...197198199200201202203204205206207208209» |
- NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health
Clinical: NovaTears® Eye Drops Observational Study (clinicaltrials.gov) - Apr 9, 2014
P=N/A, N=30, Active, not recruiting, Sponsor: Novaliq GmbH
- | otesaconazole (VT-1161) / Mycovia Pharma
Enrollment closed: A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) (clinicaltrials.gov) - Mar 13, 2014
P2, N=48, Active, not recruiting, Sponsor: Viamet Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting
- | otesaconazole (VT-1161) / Mycovia Pharma
Enrollment closed: A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis (clinicaltrials.gov) - Mar 9, 2014
P2, N=48, Active, not recruiting, Sponsor: Viamet Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment change: A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer (clinicaltrials.gov) - Dec 1, 2013
P2, N=20, Completed, Sponsor: Fudan University
Recruiting --> Active, not recruiting N=60 --> 20
- | AiTan (rivoceranib) / HLB Bio Group
Trial completion: A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer (clinicaltrials.gov) - Dec 1, 2013
P2, N=20, Completed, Sponsor: Fudan University
N=60 --> 20 Recruiting --> Completed
- | famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Enrollment change: A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer (clinicaltrials.gov) - Nov 30, 2013
P2, N=28, Completed, Sponsor: Fudan University
Recruiting --> Completed N=77 --> 28
- ||| AiTan (rivoceranib) / HLB Bio Group
Enrollment change: Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients (clinicaltrials.gov) - Nov 30, 2013
P2a, N=60, Active, not recruiting, Sponsor: Fudan University
N=77 --> 28 N=80 --> 60
- ||| AiTan (rivoceranib) / HLB Bio Group
Enrollment closed: Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients (clinicaltrials.gov) - Nov 30, 2013
P2a, N=60, Active, not recruiting, Sponsor: Fudan University
N=80 --> 60 Recruiting --> Active, not recruiting
- | famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Trial completion: A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer (clinicaltrials.gov) - Nov 30, 2013
P2, N=28, Completed, Sponsor: Fudan University
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||||| famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P2 trial: A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor (clinicaltrials.gov) - Nov 18, 2013
P2, N=63, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||||| imrecoxib (BAP 909) / Jiangsu Hengrui Pharma
New P4 trial: A Phase 4 Study of Imrecoxib in Treatment of Knee Osteoarthritis (clinicaltrials.gov) - Nov 13, 2013
P4, N=2400, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||||| besigliptin (SHR117887) / Jiangsu Hengrui Pharma
New P2 trial, Combination therapy: Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes (clinicaltrials.gov) - Nov 12, 2013
P2, N=120, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||| remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New P1 trial: A Phase ?a Study of Remimazolam Tosylate in Healthy Volunteers (clinicaltrials.gov) - Oct 21, 2013
P1, N=64, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||| remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
Enrollment open: A Phase ?a Study of Remimazolam Tosylate in Healthy Volunteers (clinicaltrials.gov) - Oct 21, 2013
P1, N=64, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
Enrollment open, Combination therapy: A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 21, 2013
P3, N=360, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
Enrollment open, Monotherapy: Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 21, 2013
P3, N=450, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
Trial completion: A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes (clinicaltrials.gov) - Oct 20, 2013
P2, N=200, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- |||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
Trial completion, Combination therapy: Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 20, 2013
P2, N=120, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Completed Not yet recruiting --> Completed
- |||||||||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P3 trial, Combination therapy: A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 17, 2013
P3, N=360, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||||||||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P3 trial, Monotherapy: Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 17, 2013
P3, N=450, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P2 trial: A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes (clinicaltrials.gov) - Oct 16, 2013
P2, N=200, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P2 trial, Combination therapy: Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 16, 2013
P2, N=120, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P1 trial: Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer (clinicaltrials.gov) - Sep 6, 2013
P1, N=40, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | otesaconazole (VT-1161) / Mycovia Pharma
New P2 trial: A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) (clinicaltrials.gov) - Jul 1, 2013
P2, N=48, Active, not recruiting, Sponsor: Viamet Pharmaceuticals, Inc.
- | otesaconazole (VT-1161) / Mycovia Pharma
New P2 trial: A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis (clinicaltrials.gov) - Jul 1, 2013
P2, N=48, Active, not recruiting, Sponsor: Viamet Pharmaceuticals, Inc.
- ||| Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New P1 trial: A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers (clinicaltrials.gov) - Apr 10, 2013
P1, N=96, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||||| famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P2 trial: A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer (clinicaltrials.gov) - Apr 9, 2013
P2, N=150, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||||||| Pegylated rhG-CSF (mecapegfilgrastim) / Jiangsu Hengrui Pharma
Trial completion: A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy (clinicaltrials.gov) - Jan 4, 2013
P3, N=330, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Completed Recruiting --> Completed
- |||||| famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P2b trial, Metastases: A Study of Famitinib in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Jan 3, 2013
P2b, N=150, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P1 trial: A Phase I Study of Famitinib Malate in Patients With Solid Tumor (clinicaltrials.gov) - Jan 3, 2013
P1, N=29, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- henatinib / Shanghai Inst. of Materia Medica, Jiangsu Hengrui Pharma
Trial termination, Metastases: A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Dec 19, 2012
P1, N=44, Terminated, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Completed Recruiting --> Terminated
- cipatinib / Jiangsu Hengrui Pharma
Trial termination: Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer (clinicaltrials.gov) - Dec 19, 2012
P1, N=26, Terminated, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Terminated Recruiting --> Terminated
- cipatinib / Jiangsu Hengrui Pharma
Enrollment change: Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer (clinicaltrials.gov) - Dec 19, 2012
P1, N=26, Terminated, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Terminated N=40 --> 26
- | AiTan (rivoceranib) / HLB Bio Group
New P1/2 trial: Dose-Escalation and Safety Trial of YN968D1 (clinicaltrials.gov) - Nov 12, 2012
P1/2, N=42, Recruiting, Sponsor: Bukwang Pharm. Co., Ltd.
- | famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P2 trial: A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer (clinicaltrials.gov) - Jul 29, 2012
P2, N=28, Completed, Sponsor: Fudan University
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer (clinicaltrials.gov) - Jul 29, 2012
P2, N=20, Completed, Sponsor: Fudan University
- |||||||||| Pegylated rhG-CSF (mecapegfilgrastim) / Jiangsu Hengrui Pharma
New P3 trial: A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy (clinicaltrials.gov) - May 31, 2012
P3, N=330, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||||| HHPG-19K (mecapegfilgrastim) / Jiangsu Hengrui Pharma
Enrollment change: A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy (clinicaltrials.gov) - May 30, 2012
P3, N=150, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
N=40 --> 26 N=390 --> 150
- |||||| HHPG-19K (mecapegfilgrastim) / Jiangsu Hengrui Pharma
Enrollment open: A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy (clinicaltrials.gov) - May 30, 2012
P3, N=150, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
N=390 --> 150 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment open: Dose-Escalation and Safety Trial of YN968D1 (clinicaltrials.gov) - Apr 25, 2012
P1/2, N=42, Recruiting, Sponsor: LSK BioPartners Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| HHPG-19K (mecapegfilgrastim) / Jiangsu Hengrui Pharma
New P3 trial: A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy (clinicaltrials.gov) - Mar 20, 2012
P3, N=150, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment closed: Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - Feb 11, 2012
P3, N=480, Active, not recruiting, Sponsor: Sun Yat-sen University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| AiTan (rivoceranib) / HLB Bio Group
Trial completion: A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer (clinicaltrials.gov) - Feb 8, 2012
P2, N=136, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting Recruiting --> Completed
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer (clinicaltrials.gov) - Feb 6, 2012
P2, N=40, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||||||||| AiTan (rivoceranib) / HLB Bio Group
New P3 trial, Metastases: Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Jan 12, 2012
P3, N=270, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group
Trial initiation date: Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 3, 2012
P3, N=480, Active, not recruiting, Sponsor: Sun Yat-sen University
Recruiting --> Completed Initiation date: Mar 2010 --> Apr 2011
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment change: Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 3, 2012
P3, N=480, Active, not recruiting, Sponsor: Sun Yat-sen University
Initiation date: Mar 2010 --> Apr 2011 N=137 --> 480
- ||||| Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
New P2 trial: A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (clinicaltrials.gov) - Jan 2, 2012
P2, N=150, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group
New P1/2 trial: Dose-Escalation and Safety Trial of YN968D1 (clinicaltrials.gov) - Dec 20, 2011
P1/2, N=42, Recruiting, Sponsor: LSK BioPartners Inc.
- | famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P1 trial, Metastases: FMTN-I-LNPC: Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov) - Oct 26, 2011
P1, N=21, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.